



Allergologia et immunopathologia

Sociedad Española de Inmunología Clínica,
Alergología y Asma Pediátrica

www.elsevier.es/ai



REVIEW

Biologics in chronic urticaria

M. Ferrer*, R. Madamba



Department of Allergology and Clinical Immunology, Clinica Universidad de Navarra, Pamplona, Spain

Available online 3 November 2017

Introduction

Chronic spontaneous urticaria (CSU) consists in the appearance of hives with or without angioedema for more than 6 weeks duration. It is a highly disabling disease, with a great impact on the patient's quality of life.¹ There are intermittent urticarias elicited by physical stimuli now classified as chronic inducible urticarias (CINDU) that comprise cholinergic urticaria, cold urticaria, dermatographism, local heat urticaria and aquagenic urticaria. This review will be focusing on CSU.

Up to the very moment, the pathophysiology of CSU remains elusive,² with several cells and mediators being involved thus possibly indicates that this medical condition affects not only one target. Antihistamines have been the mainstay treatment for CSU. Antihistamines can control the disease in 38% of cases and increasing its dose can control only up to 60% of cases.³ Despite following the recommendation from the present guidelines that antihistamines can be given up to 4 times a day, a significant percentage of patients still remain symptomatic.⁴ In uncontrolled cases with antihistamines, double blinded placebo controlled studies showed that cyclosporine is efficient to control urticaria and even improves after discontinuing the above mentioned medication.^{5,6} However, it is an off-label treatment with serious systemic side effects such as the need of regular monitorization of blood pressure as well as renal function.

In the recent years, a number of biologics were developed that showed very good results to allergic diseases.⁷ In this

review, we will cover the biologic agents that were indicated and investigated for CSU most especially Omalizumab.

Biologics are large molecular weight molecules produced in living organisms that bind to a specific determinant such as cytokines, receptors or other immunoglobulins. They allow the delivery of a personalized medication but at the same time, the knowledge of the exact mechanism to target specific players of each disease is vital. There is a recent published article with an excellent review on the updates of biologics in allergic diseases.⁸

Rituximab

Rituximab is a chimeric monoclonal antibody that binds to the CD20 surface B cells receptor causing a depletion of B cells. It has been widely used for autoimmune disorders characterized by a high B cell number. The reason of using Rituximab for CSU is based on the presence of IgG against the FcεRII receptor, depleting B cells hence resulting to a decrease of IgG production.

There are two case reports: one in a 12-year-old and another in an adult patient^{9,10} with severe and difficult to treat urticaria. Both patients received Rituximab. Corticosteroids or cyclosporine were not administered due its side effects. After four injections of Rituximab, both patients showed a very good response and were noted to be asymptomatic even on follow up after several months.

There is a negative case report outcome in a CSU patient associated with delayed pressure urticaria non-responsive to several immunosuppressants such as cyclosporine or¹¹ methylprednisolone that neither responded to Rituximab.

In conclusion, further studies are needed in order to validate the effectivity of Rituximab in urticaria. We are not

* Corresponding author.

E-mail address: mferrerp@unav.edu (M. Ferrer).

aware of ongoing clinical trials with Rituximab as of the moment.

TNF-alpha inhibitors

TNF-alpha has multiple actions in the immune system such as inducing secretion of several cytokines, adhesion molecules and T cell migration that offers a target for treatment of several inflammatory conditions like rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). There are several TNF-alpha antagonists available in the market: Etanercept, Infliximab, Adalimumab, Golimumab and Certolizumab Pegol that are reviewed elsewhere.¹²

The group of inhibitors of TNF-alpha have been tried for urticaria based on reports that found higher levels of TNF-alpha in CSU lesions.^{13,14} Mast cells are a source of TNF-alpha thus could possibly play a role. Its use in urticaria was first reported in a patient diagnosed with psoriasis with severe delayed pressure urticaria,¹⁵ who showed a complete response after treatment with Etanercept and later on with Infliximab. The other study comprised six severe CSU patients who did not respond to multiple therapies.¹⁶ Four were treated with Etanercept, one with Adalimumab and one with Infliximab with a very good response. Interestingly, three patients treated with Etanercept were free of lesions after 3 years, 2 years and 7 months respectively with no other add-on treatment needed. Another patient that did not respond to Etanercept switched to Infliximab plus Methotrexate, still had occasional hives. The fifth patient was clear of lesions for 9 months after discontinuing Adalimumab. The sixth patient was still ongoing treatment with Etanercept, well controlled upon the publication of this article.

There is a completed Phase I/II Open-label study with one anti-TNF-alpha, Abatacept however, results are not yet published.¹⁷

Unfortunately, TNF-alpha inhibitor has significant side effects mainly tuberculosis, neutropenia, serious infections, heart failure, and malignancy which places the indication of TNF-alpha for severe cases and unresponsive to other available therapies.

Omalizumab

Omalizumab (OmAb) is a recombinant humanized monoclonal antibody that binds to free immunoglobulin E on the C epsilon 3 locus¹⁸⁻²⁰ of the constant fragment. It recognizes an epitope that is masked when IgE is bound to its high-affinity receptor, Fc epsilon receptor 1 (FcεRI). Consequently, it inhibits mast cells and basophil activation and the allergic reaction and inflammation.²¹ The reduction of circulating IgE causes a reduction of FcεRI in mast cells²² and basophils.²³

The rationale for utilizing Omalizumab for CSU is supported by the fact that sera from a subset of patients with chronic spontaneous urticaria (CSU) was demonstrated to activate normal basophils²⁴ and mast cells²⁵ through IgG antibodies against the alpha subunit IgE receptor^{26,27} or against IgE.²⁷ Therefore, sequestering IgE would cause FcεRI

endocytosis and antigen disappearance. FcεRI internalization occurs over several weeks.²⁸

The first case report²⁹ on the efficacy of Omalizumab for CSU was done in 2007, establishing a very good response in CSU recalcitrant to conventional therapy. The first proof of concept was reported by Kaplan³⁰ in 2008 in a single blind and placebo controlled study with 12 autoimmune severe CSU patients, demonstrating a significant response in 11 among 12 patients with a response rate of 60%; remarkably, all patients had severe, prolonged and resistant to therapy of CSU. In 2011, two double blinded placebo controlled studies were performed. The first one³¹ was a randomized study wherein patients received 75, 300 or 600 mg respectively of Omalizumab in addition to the antihistamine dose that they were taking. The patients showed a significant improvement in the UAS7 score with the 300 mg dose. Soon after, Ferrer reported in an observational study that Omalizumab was equally effective in patients with non autoimmune CSU subtype,³² as it was reported for autoimmune. Shortly thereafter, two Phase III studies^{33,34} reported a remarkable response in patients suffering CSU that did not respond to previous treatments. It was approved for CSU by the FDA and EMEA.

These findings were confirmed with real life reports³⁵⁻³⁷ that find better results with higher percentage of response than in the clinical trials.

Omalizumab also showed effectivity upon reintroduction³⁸ so it signifies that it does not induce antibody production.

The exact mechanism of action is not well known. In contrast of what is believed, Eggel demonstrated that Omalizumab is indeed able to remove already bound to its receptor^{39,40} causing a decrease in basophil activation. This was later confirmed by Serrano-Candelas et al.⁴¹ demonstrating not only a decrease in basophil function and mast cells upon incubation with Omalizumab but also a downregulation of proximal and distal signaling molecules. However, clinical response could not be correlated with any in vitro parameter.

Other anti-IgE antibodies

There is a recent publication of the result of a clinical study with Quilizumab that included 45 CSU patients. Quilizumab is a monoclonal antibody that binds to the M1-prime segment of the IgE membrane that causes an IgE depletion and cell apoptosis. This clinical trial was not effective.⁴²

Furthermore, there is an ongoing clinical trial involving another anti-IgE, Ligelizumab,⁴³ a humanised monoclonal IgG1κ antibody with a high avidity for IgE with no published result.

Conclusion

With the discovery of biologicals, specially Omalizumab, the CSU prospective has significantly changed thus offering better control of the disease as well as a better rate of response in real life reaching almost 85% of patients. However, there are many challenges ahead. We need to identify the predictive markers for the non-responders, generate the best administration protocol, define the non-responders and

principally to investigate further in order to determine the exact mechanism of action.

Once the mechanism of action is known, we will be able to design other biologics that will not only control the disease but will also cure the medical condition.

Conflict of interest

M Ferrer has served in Advisory Board, speaker fees and research grant from Novartis. R Madamba have have no conflict of interest to declare. All applicable international, national, and/or institutional guidelines for manuscript authorships were followed.

References

- Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. *Allergy*. 2003;58:621–3.
- Ferrer M. Immunological events in chronic spontaneous urticaria. *Clin Transl Allergy*. 2015;5:1–8.
- Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, Ferrer M. Up-dosing non-sedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. *Br J Dermatol*. 2016.
- Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. *Allergy*. 2014;69:868–87.
- Grattan CE, Bf OD, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. *Br J Dermatol*. 2000;143:365–72.
- Vena GA, Cassano N, Colombo D, Peruzzi E, Pigatto P, the NEO. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. *J Am Acad Dermatol*. 2006;55:705–9.
- Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A, et al. EAACI IG biologics task force paper on the use of biologic agents in allergic disorders. *Allergy*. 2015;70:727–54.
- Landolina N, Levi-Schaffer F. Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. *Br J Pharmacol*. 2016;173:793–803.
- Arkwright PD. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. *J Allergy Clin Immunol*. 2009;123:510–1 [author reply 1].
- Chakravarty SD, Yee AF, Paget SA. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. *J Allergy Clin Immunol*. 2011;128:1354–5.
- Mallipeddi R, Grattan CE. Lack of response of severe steroid-dependent chronic urticaria to rituximab. *Clin Exp Dermatol*. 2007;32:333–4.
- Atzeni F, Sarzi-Puttini P. Anti-cytokine antibodies for rheumatic diseases. *Curr Opin Investig Drugs*. 2009;10:1204–11.
- Hermes B, Prochazka AK, Haas N, Jurgovsky K, Sticherling M, Henz BM. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. *J Allergy Clin Immunol*. 1999;103:307–14.
- Piconi S, Trabattini D, Iemoli E, Fusi ML, Villa ML, Milazzo F, et al. Immune profiles of patients with chronic idiopathic urticaria. *Int Arch Allergy Immunol*. 2002;128:59–66.
- Magerl M, Philipp S, Manasterski M, Friedrich M, Maurer M. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. *J Allergy Clin Immunol*. 2007;119:752–4.
- Wilson LH, Eliason MJ, Leiferman KM, Hull CM, Powell DL. Treatment of refractory chronic urticaria with tumor necrosis factor-alpha inhibitors. *J Am Acad Dermatol*. 2011;64:1221–2.
- Abatacept. 2016.
- Zheng L, Li B, Qian W, Zhao L, Cao Z, Shi S, et al. Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab. *Biochem Biophys Res Commun*. 2008;375:619–22.
- Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. *J Immunol*. 1993;151:2623–32.
- Babu KS, Polosa R, Morjaria JB. Anti-IgE – emerging opportunities for Omalizumab. *Expert Opin Biol Ther*. 2013;13:765–77.
- Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E. Omalizumab, an anti-immunoglobulin E antibody: state of the art. *Drug Des Dev Ther*. 2014;8:197–207.
- Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. *J Allergy Clin Immunol*. 2004;114:527–30.
- MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. *J Immunol*. 1997;158:1438–45.
- Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. *N Engl J Med*. 1993;328:1599–604.
- Niimi N, Francis DM, Kermani F, O'Donnell BF, Hide M, Kobza-Black A, et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. *J Invest Dermatol*. 1996;106:1001–6.
- Fiebigler E, Maurer D, Holub H, Reininger B, Hartmann G, Woisetschlager M, et al. Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? *J Clin Invest*. 1995;96:2606–12.
- Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria. *J Allergy Clin Immunol*. 1998;101:672–6.
- Saini SS, MacGlashan DW Jr, Sterbinsky SA, Togias A, Adelman DC, Lichtenstein LM, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. *J Immunol*. 1999;162:5624–30.
- Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. *Ann Allergy Asthma Immunol*. 2007;99:190–3.
- Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. *J Allergy Clin Immunol*. 2008;122:569–73.
- Saini S, Rosen KE, Hsieh H-J, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. *J Allergy Clin Immunol*. 2011;128:567–73.
- Ferrer M, Gamboa P, Sanz ML, Goikoetxea MJ, Cabrera-Freitag P, Javaloyes G, et al. Omalizumab is effective in nonautoimmune urticaria. *J Allergy Clin Immunol*. 2011;127:1300–2.
- Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med*. 2013;368:924–35.
- Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. *J Allergy Clin Immunol*. 2013;132:101–9.
- Labrador-Horrillo M, Valero A, Velasco M, Jauregui I, Sastre J, Bartra J, et al. Efficacy of omalizumab in chronic spontaneous

- urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice. *Exp Opin Biol.* 2013;13:1225–8.
36. Buyukozturk S, Gelincik A, Demirturk M, Kocaturk E, Colakoglu B, Dal M. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. *J Dermatol.* 2012.
 37. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. *J Dermatol Sci.* 2014;73:57–62.
 38. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. *JAMA Dermatol.* 2014;150:288–90.
 39. Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPIn-Fc fusion protein. *Allergy.* 2011;66:961–8.
 40. Eggel A, Baravalle G, Hobi G, Kim B, Buschor P, Forrer P, et al. Accelerated dissociation of IgE-FcεpsilonRI complexes by disruptive inhibitors actively desensitizes allergic effector cells. *J Allergy Clin Immunol.* 2014;133, 1709–19 e8.
 41. Serrano-Candelas E, Martinez-Aranguren R, Valero A, Bartra J, Gastaminza G, Goikoetxea MJ, et al. Comparable actions of omalizumab on mast cells and basophils. *Clin Exp Allergy.* 2016;46:92–102.
 42. Harris JM, Cabanski CR, Scheerens H, Samineni D, Bradley MS, Cochran C, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. *J Allergy Clin Immunol.* 2016.
 43. Ligelizumab. <https://clinicaltrials.gov/ct2/show/NCT02477332?term=ligelizumab&rank=10> [accessed 13.11.16], 2016.